Mitsuhiro Rokuda

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 14

Top Topics

Rheumatoid Arthritis

Top Venues

Journal of diabetes investigation

Modern rheumatology

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Yoko Yoshinaga, Mitsuhiro Rokuda
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis. Journal of diabetes investigation 15 (3) (2023)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Yoko Yoshinaga, Mitsuhiro Rokuda
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis. Journal of diabetes investigation 15 (3) (2023)
Hirokazu Takahashi, Keiko Asakawa, Yoshinori Kosakai, Takumi Lee, Mitsuhiro Rokuda
Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis. Diabetes, obesity & metabolism (2023)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Yoko Yoshinaga, Mitsuhiro Rokuda
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis. Journal of diabetes investigation 15 (3) (2023)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Yoko Yoshinaga, Mitsuhiro Rokuda
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis. Journal of diabetes investigation 15 (3) (2023)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Yoko Yoshinaga, Mitsuhiro Rokuda
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis. Journal of diabetes investigation (2023)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Tadashi Koga, Keiko Asakawa, Mitsuhiro Rokuda
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. Journal of diabetes investigation 14 (3) (2022)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Tadashi Koga, Keiko Asakawa, Mitsuhiro Rokuda
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. Journal of diabetes investigation 14 (3) (2022)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Tadashi Koga, Keiko Asakawa, Mitsuhiro Rokuda
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. Journal of diabetes investigation (2022)
Yoshiya Tanaka, Tsutomu Takeuchi, Daisuke Kato, Yuichiro Kaneko, Musashi Fukuda, Hiroyuki Izutsu, Mitsuhiro Rokuda
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years. Modern rheumatology 32 (4) (2022)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Tadashi Koga, Keiko Asakawa, Mitsuhiro Rokuda
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. Journal of diabetes investigation 14 (3) (2022)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Tadashi Koga, Keiko Asakawa, Mitsuhiro Rokuda
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. Journal of diabetes investigation 14 (3) (2022)
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, Tadashi Koga, Keiko Asakawa, Mitsuhiro Rokuda
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan. Journal of diabetes investigation 14 (3) (2022)
Tsutomu Takeuchi, Yoshiya Tanaka, Mitsuhiro Rokuda, Hiroyuki Izutsu, Yuichiro Kaneko, Musashi Fukuda, Daisuke Kato
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. Modern rheumatology 31 (3) (2020)